You are here: Industry Insights > Perrigo

News List

Perrigo to sell Tysabri royalty stream to Royalty Pharma for up to $2.85 billion firstwordpharma
February 28, 2017
Perrigo announced Monday that it signed a definitive agreement to divest its rights to the royalty stream from global net sales of the multiple sclerosis drug Tysabri (natalizumab) to Royalty Pharma in a deal worth as much as $2.85 billion.
FDA Approves Perrigo’s Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution americanpharmaceuticalreview
February 22, 2017
Perrigo Company has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL.
Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral S firstwordpharma
February 20, 2017
Perrigo Company plc (NYSE, TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL.
Perrigo reaches deal with investor to replace five board members firstwordpharma
February 08, 2017
Perrigo announced Tuesday that under an agreement with investor Starboard Value, five new members will be appointed to the drugmaker's board.
Perrigo Confirms Patent Challenge for Generic Version of Onexton® Gel americanpharmaceuticalreview
February 08, 2017
Perrigo Company has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for clindamycin, benzoyl peroxide topical gel, the generic version of Onexton® gel (clindamycin phosphate 1.2% and benzoyl peroxide
Perrigo Updates Segment Reporting Structure americanpharmaceuticalreview
January 11, 2017
Perrigo Company has changed its reporting segments to better align with the Company's organizational structure. Beginning with the fourth quarter of calendar year 2016, the company's new reporting segments are:

Previous page 1 2 3 Next page